AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 29, 2025 7:45 am ET1min read
Aime SummaryAIM ImmunoTech Inc (AIM) experienced a significant drop of 38.33% in pre-market trading on July 29, 2025, due to a trading halt triggered by volatility. This measure is typically implemented to ensure orderly trading during periods of substantial price movements, which can influence market behavior and future stock performance.
Analysts have set a one-year price target for
Inc, with an average estimate of $150.00, indicating a potential upside of 910.10% from the current price. This optimistic outlook is supported by a consensus recommendation of "Outperform" from brokerage firms, suggesting a strong buy signal for the stock.GuruFocus estimates the fair value of AIM ImmunoTech Inc to be $31.16 in one year, implying a 109.83% upside from the current price. This estimate is based on historical trading multiples, past business growth, and future performance projections, providing a comprehensive view of the stock's potential value.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet